Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 6Phase 1/2 2Phase 3 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Thymoma 1Small Cell Lung Carcinoma 1Kidney Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × vorolanib × Clear all
NCT03583086 2024-10-08

Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors

Vanderbilt-Ingram Cancer Center

Phase 1/2 Completed
88 enrolled 20 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Thymoma, Small Cell Lung Carcinoma

NCT06577961 2024-08-29

Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1/2 Not yet recruiting
37 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡